Verisante Technology, Inc. has announced that a research study using its Core laser Raman spectroscopy system was named as one of the Canadian Cancer Society’s 10 research achievements for 2011.

“2011 has been a very exciting year for cancer research,” said the Canadian Cancer Society’s Sarah Bouma. “Society funded researchers have made tremendous gains, particularly in clinical trials. Research advances across the country are impacting the lives of people living with cancer, their families and caregivers.”

In July 2011, Verisante announced the results of a pilot study on lung cancer detection led by Dr Stephen Lam and Dr Haishan Zeng and conducted at the Lung Centre at Vancouver General Hospital. Results were published in the Journal of Thoracic Oncology. The study, funded by the Canadian Cancer Society, used the Verisante Core laser Raman spectroscopy system, which was able to detect pre-cancerous lung lesions with 96% sensitivity and 91% specificity when used in combination with existing methods. The application of the Core could improve early detection of lung cancer and reduce the number of false positives associated with other methods. www.verisante.com

User Rating: / 0
PoorBest